|Systematic (IUPAC) name|
|Trade names||EVO (Beximco, Bangladesh),Levaquin, Quixin|
|Licence data||US FDA:|
|Pregnancy cat.||C (US)|
|Legal status||℞ Prescription only|
|Routes||Oral, IV, ophthalmic|
|Protein binding||24 to 38%|
|Half-life||6 to 8 hours|
|ATC code||J01 S01|
|Synonyms||(S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl) -7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij] quinoline-6-carboxylic acid|
|Mol. mass||361.368 g/mol|
|(what is this?)|
Levofloxacin (Levaquin (U.S.), Tavanic (E.U.), and others) is a broad spectrum antibiotic of the fluoroquinolone drug class. Its spectrum of activity includes most strains of bacterial pathogens responsible for respiratory, urinary tract, gastrointestinal, and abdominal infections, including Gram negative (Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Moraxella catarrhalis, Proteus mirabilis, and Pseudomonas aeruginosa), Gram positive (methicillin-sensitive but not methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Staphylococcus epidermidis, Enterococcus faecalis, and Streptococcus pyogenes), and atypical bacterial pathogens (Chlamydophila pneumoniae and Mycoplasma pneumoniae). Levofloxacin and other fluoroquinolones are valued for this broad spectrum of activity, excellent tissue penetration, and for their availability in both oral and intravenous formulations. (Many antibacterials used in serious infections must be dosed intravenously.) Levafloxacin is used alone or in combination with other antibacterial drugs to treat certain bacterial infections including pneumonia, urinary tract infections, and abdominal infections.
Levofloxacin is a chiral fluorinated carboxyquinolone. Investigation of ofloxacin, an older drug that is the racemic mixture, found that the (–)-(S) enantiomer (also known as the S isomer) is more active. This specific component is levofloxacin. Levofloxacin and other fluoroquinolones are generally well tolerated, but in rare instances have produced serious adverse reactions such as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon damage may manifest months after therapy had been completed and in severe cases may result in lifelong disabilities. Levofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Such an adverse reaction is a potentially life-threatening event and may require ventilatory support.
Other controversies associated with this drug include increasing resistance due to their overuse. This overuse includes situations in which antibiotic therapy is unnecessary, and others in which the use of a less broad spectrum agent would produce equivalent results.
- 1 Medical uses
- 2 Contraindications
- 3 Special precautions
- 4 Adverse effects
- 5 Overdose
- 6 Pharmacology
- 7 Pharmacokinetics
- 8 Mechanism of action
- 9 Interactions
- 10 History
- 11 Antibiotic abuse and bacterial resistance
- 12 Social and economic impact
- 13 Current litigation
- 14 References
- 15 External links
Levofloxacin is used to treat infections including: respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, endocarditis, meningitis, pelvic inflammatory disease, traveler's diarrhea, tuberculosis and plague.
In the adult population oral and I.V. levofloxacin is used for the treatment of bacterial infections such as:
- Urinary Tract Infections Added 17 December 1998
- Skin and Skin Structure Infections Added 9/8/2000
- Inhalational Anthrax (Post-Exposure)Added 24 November 2004
- Acute Bacterial Exacerbation of Chronic Bronchitis Added 23 June 2006
- Acute Pyelonephritis Added 23 June 2006
- Pneumonic plague and septicemic plague (Yersinia pestis) and prophylaxis in adults and pediatric patients, 6 months of age and older.
Within the pediatric population Oral and I.V. levofloxacin is limited to:
- Inhalational Anthrax (Post-Exposure) Added 5 May 2008
Note: Levofloxacin has shown moderate activity against anaerobes, and is about twice as potent as ofloxacin against mycobacterium tuberculosis and other mycobacteria, including mycobacterium avium complex.
Oral and I.V. Levaquin are not licensed by the FDA for use in children other than the exception (inhalational anthrax), due to the risk of injury to the musculoskeletal system. Levofloxacin is not to be considered a first line agent for inhalational anthrax in the pediatric population due to severe adverse reactions involving the musculoskeletal system and other serious adverse reactions.
The fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.
Note: levofloxacin may be licensed for other uses, or restricted, by the various regulatory agencies worldwide.
Levofloxacin is available in tablet form, injection, oral solution, as well as used in prescription eye and ear drops.
There is one contraindication now found within the 2008 package insert for Levaquin, namely that Levaquin is to be avoided in patients with a known hypersensitivity to levofloxacin or other quinolone drugs.
According to the FDA approved Prescribing Information, levofloxacin is Pregnancy Category C. This designation indicates that animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans but the potential benefit to the mother may in some cases outweigh the risk to the fetus. Other flouroquinolones have also been reported as being present in the mother's milk and are passed on to the nursing child.
- Pediatric use
Oral and I.V. Levofloxacin is not licensed for use in the pediatric population, except as noted above, due to the risk of injury to the pediatric patient. In one study, 1534 juvenile patients (age 6 months to 16 years) treated with levofloxacin as part of three efficacy trials were followed up to assess all musculoskeletal events occurring up to 12 months post-treatment. At 12 months follow-up the cumulative incidence of musculoskeletal adverse events was 3.4%, compared to 1.8% among 893 patients treated with other antibiotics. In the levafloxacin-treated group, approximately two-thirds of these musculoskeletal AEs occurred in the first 60 days, 86% were mild, 17% were moderate, and all resolved without long-term sequelae.
In a study comparing the safety and efficacy of levofloxacin to that of azithromycin or the ceftriaxone in 712 children with community-acquired pneumonia, serious adverse events were experienced by 6% of those treated with levofloxacin and 4% of those treated with comparator antibiotics. Most of these were considered by the treating physician to be unrelated or doubtfully related to the study drug. Two deaths were observed in the levofloxacin group, neither of which was thought to be treatment-related. Spontaneous reports to the FDA Adverse Effects Reporting System at the time of the 20 September 2011 FDA Pediatric Drugs Advisory Committee include musculoskeletal events (39, including 5 cases of tendon rupture) and CNS events (19, including 5 cases of seizures) as the most common spontaneous reports between April 2005 and March 2008. An estimated 130,000 pediatric prescriptions for levofloxacin were filled on behalf of 112,000 pediatric patients during that period.
Levofloxacin should be administered only as described within the Dosage Guidelines table found within the most current package insert. The status of the patient's renal function and hepatic function must also be taken into consideration to avoid an accumulation that may lead to a fatal drug overdose. Levofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the liver and the intestine. Modification of the dosage is recommended using the table found within the package insert for those with impaired liver or kidney function (particularly for patients with severe renal dysfunction). Within the package insert, it is stated "...since the drug is known to be substantially excreted by the kidneys, the risk of toxic reactions to this drug may be greater in patients with impaired renal function." The duration of treatment depends upon the severity of infection, in the range of 3 days to 60 days.
Most adverse reactions are mild to moderate; however, on occasion, serious adverse effects occur. additional warnings and safety information added to the package inserts, which includes boxed warnings together with the issuance of "Dear Doctor Letters" concerning the recent addition of the boxed warning.
In 2004, the FDA requested new warning labels to be added to all of the Fluoroquinolones, including levofloxacin, regarding peripheral neuropathy (irreversible nerve damage), tendon damage, heart problems (prolonged QT Interval / Torsades de pointes), Pseudomembranous colitis, Rhabdomyolysis (muscle wasting), Stevens-Johnson Syndrome, as well as concurrent usage of NSAIDs contributing to the severity of these reactions.
Subsequent to this, on 25 June 2007, the FDA required the manufacturer to add an additional warning to the package inserts that stated that "Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain etiology, have been reported in patients receiving therapy with quinolones, including levofloxacin."
The serious adverse effects that may occur as a result of levofloxacin therapy include irreversible peripheral neuropathy, spontaneous tendon rupture and tendonitis, QTc prolongation/torsades de pointes, toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome, erythema multiforme, severe central nervous system disorders (CNS), including seizures and clostridium difficile associated disease (CDAD: Pseudomembranous colitis) photosensitivity/phototoxicity reactions, fatal hypoglycemia, kidney damage, rhabdomyolysis (muscle wasting), as well as anaphylactoid reactions and myasthenia crisis.
Additional serious adverse reactions include acute pancreatitis, temporary as well as loss of vision, irreversible double vision, impaired color vision, exanthema, abdominal pain, malaise, drug fever, dysaesthesia and eosinophilia. Pseudotumor cerebri, commonly known as idiopathic intracranial hypertension (IIH), (also referred to as increased intracranial pressure), has been reported to occur as a serious adverse reaction to levofloxacin. Another serious adverse effect is autoimmune hemolytic anemia.
Older patients may have an increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use, and such patients may also be more susceptible to prolongation of the QT interval. Patients with known prolongation, those with hypokalemia, or being treated with other drugs that prolong the QT interval should avoid the use of Levaquin. Hematologic reactions (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses.
Children and the elderly are at a much greater risk of experiencing such adverse reactions. Such reactions may manifest during, as well as long after fluoroquinolone therapy had been discontinued.
Serious visual complications have also been reported to occur with ophthalmic fluoroquinolone therapy, which may also occur with levofloxacin eye drops, especially corneal perforation, but also evisceration and enucleation. This increased incidents of corneal perforation may be due to fluoroquinolones causing alterations in stromal collagen, leading to a reduction in tectonic strength. As noted previously double vision (diplopia) has also been reported.
Some groups refer to these adverse events as "fluoroquinolone toxicity". These groups of people claim to have suffered serious long term harm to their health from using fluoroquinolones. This has led to a class action lawsuit by people harmed by the use of fluoroquinolones as well as legal action by the consumer advocate group Public Citizen. Partly as a result of the efforts of The State of Illinois and Public Citizen the FDA ordered a boxed warning on all fluoroquinolones advising consumers of the possible toxic effects of fluoroquinolones on tendons.
In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.
Levofloxacin is the L-isomer of the racemate ofloxacin, a quinolone antimicrobial agent. In chemical terms, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate. The empirical formula is C18H20FN3O4 • ½ H2O, and the molecular weight is 370.38 g/mol. Levofloxacin is a light-yellowish-white to yellow-white crystal or crystalline powder.
Some of the endogenous compounds that are affected by the levofloxacin include GABA receptors (inhibitor), OCTN2 (inhibitor), blood glucose (alteration) potassium channels (in myocardial cells – inhibitor), pancreatic β-cell potassium channels (inhibitor) and glutathione (depletor). Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers and can fulfil the criteria for a positive comparator. The ICH E14 guidelines recommend a threshold of around 5 ms for a positive QT/QTc study. The largest time-matched difference in QTc for levofloxacin suggests the potential for use in more rigorous QT/QTc studies.
Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Levofloxacin is rapidly and, in essence, completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for LEVAQUIN Tablets when equal doses (mg/mg) are administered. Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. Glucuronidation and hydroxylation have been cited as one of the major metabolic pathways for levofloxacin hydrochloride. However the drug card for levofloxacin (DB01137) states that the biotransformation information is not available. Specific information regarding biotransformation does not appear to be readily available within the package inserts.
Mechanism of action
Levofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase iv, which is an enzyme necessary to separate replicated DNA, thereby inhibiting cell division. This can also affect mammalian cell replication. In particular, some congeners of this drug family display activity not only against bacterial topoisomerases but also against eukaryotic topoisomerases, and are toxic to cultured mammalian cells and in vivo tumor models.
Levofloxacin interacts with other drugs, as well as herbal and natural supplements. Such interactions increase the risk of cardiotoxicity and arrhythmias, anticoagulation, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.
The toxicity of drugs that are metabolised by the cytochrome P450 system is enhanced by concomitant use of some quinolones. Coadministration may dangerously increase warfarin (Coumadin) activity; INR should be monitored closely. They may also interact with the GABA A receptor and cause neurological symptoms; this effect is augmented by certain non-steroidal anti-inflammatory drugs. Quercetin, a flavonol, a kind of flavonoid, occasionally used as a dietary supplement, may interact with fluoroquinolones, as quercetin competitively binds to bacterial DNA gyrase. Some foods such as garlic and apples contain high levels of quercetin; whether this inhibits or enhances the effect of fluoroquinolones is not entirely clear.
Specific drug interaction studies have not been conducted with levofloxacin. However, the systemic administration of some quinolones has been shown to interfere with the metabolism of caffeine, elevate plasma concentrations of theophylline, and enhance the effects of the warfarin and its derivatives. In patients receiving systemic cyclosporine concomitantly, transient elevations in serum creatinine has been noted.
Significant drug interactions
Levofloxacin has been reported to interact with other drugs, as well as herbal and natural supplements. Such interactions increased the risk of cardiotoxicity and arrhythmias, anticoagulant effects, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.
Some drug interactions are associated with molecular structural modifications of the quinolone ring, specifically interactions involving NSAIDS and theophylline. Ciprofloxacin has been shown to interact with thyroid medications (levothyroxine) resulting in unexplained hypothyroidism. As such it is possible that levofloxacin may interact with thyroid medications as well.
The use of NSAIDs (Non-Steroid Anti-Inflammatory Drugs) while undergoing fluoroquinolone therapy is contraindicated due to the risk of severe CNS adverse reactions, including but not limited to seizure disorders. Fluoroquinolones with an unsubstituted piperazinyl moiety at position 7 have the potential to interact with NSAIDs and/or their metabolites, resulting in antagonism of GABA neurotransmission. Whether or not such reactions occur after completion of therapy is unclear. Patients have reported reactions to NSAIDS long after completion of fluoroquinolone therapy, but there does not appear to be any research that would either confirm or deny this association other than these anecdotal reports.
Some quinolones exert an inhibitory effect on the cytochrome P-450 system, thereby reducing theophylline clearance and increasing theophylline blood levels. Coadministration of certain fluoroquinolones and other drugs primarily metabolized by CYP1A2 (e.g., theophylline, methylxanthines, tizanidine) results in increased plasma concentrations and could lead to clinically significant side-effects of the coadministered drug. In addition, other fluoroquinolones, especially enoxacin, and to a lesser extent ciprofloxacin and pefloxacin, also inhibit the metabolic clearance of theophylline.
Such drug interactions appear to be related to the structural changes of the quinolone ring and the inhibitory effect on the cytochrome P-450 system. As such, these drug interactions involving the fluoroquinolones appear to be drug-specific rather than a class effect.
Current or past treatment with oral corticosteroids is associated with an increased risk of Achilles tendon rupture, especially in elderly patients also taking the fluoroquinolones. This effect seems to be restricted to people aged 60 or over and within this group concomitant use of corticosteroids increases this risk substantially.
Fluoroquinolones are associated with false-positive results for opiates on urine opiate screening drug test. Of the fluoroquinolones, Ofloxacin and Levofloxacin are most likely to cause false positive results. Most levels detected are below (2000 ng/mL). A false-positive result may be ruled out by using a more specific test, usually gas chromatography/mass spectrometry (GC-MS). Therefore, any patient who screens positive for opiates but denies taking them and has recently taken a Fluoroquinolone should be offered more specific testing.
Cardiac antidysrhythmics that prolong the QT interval should not be used in combination with levofloxacin due to the risk of torsades and R on T syndrome. Common medications still in use today include amiodarone, tykosin, and propafenone. Older medication such as ethmozine, quinidine, and mexilitine should be avoided as well.
Levofloxacin is a fluoroquinolone antibiotic, marketed by Sanofi-Aventis under the tradename "Tavanic". Levaquin is also marketed worldwide for oral and IV use, as well as used in ophthalmic solutions. Daiichi Sankyo had granted an exclusive license to Sanofi-Aventis to make, use and sell pharmaceutical preparations containing levofloxacin in the UK and Mexico. Other manufacturers include Novell Pharmaceutical Laboratories (Levores).
Levaquin has proven to be a blockbuster drug for Johnson and Johnson / Ortho McNeil, generating billions of dollars in additional revenue. In 2007 alone, Levaquin accounted for 6.5% of Johnson and Johnson's total revenue, generating $1.6 billion, an 8% increase over the previous year. Ranking 37th within the top 200 prescribed drugs in the United States for 2007, and ranked 19th in world sales in 2007, total sales for Levaquin were in excess of 1.6 billion dollars. Levaquin was the most prescribed fluoroquinolone drug in the world for 2007.
Levofloxacin was first patented in 1987 (Levofloxacin European patent – Daiichi Pharmaceutical Co., Ltd.) and was approved by the United States Food and Drug Administration on 20 December 1996 for use in the United States to treat bacterial sinusitus, bacterial exacerbations of bronchitis, community-acquired pneumonia, uncomplicated skin infections, complicated urinary tract infections, and acute pyelonephritis. Levofloxacin is described in some publications as a second generation fluoroquinolone. Other publications describe it as a third-generation fluoroquinolone.
Levofloxacin is considered to be same as Ofloxacin by the U.S. Food and Drug Administration (FDA), with the exception of the potency shown in vitro against mycobacteria. In vitro, it is, in general, twice as potent as ofloxacin, whereas d-ofloxacin is less active against mycobacteria.
The current United States patent is held by Ortho-McNeil-Janssen. Ranked 19th in world sales in 2007, sales for Levaquin exceeded $1.4 billion. Levaquin was the most prescribed fluoroquinolone drug in the world for 2007.
Levaquin sample boxes showed a macron over the letter "e," indicating pronunciation with a long-"e" sound, although Merriam-Webster indicates a short-"e" pronunciation. Levofloxacin would typically be pronounced with the long-e from the Latin prefix "levo-" (meaning left).
In addition, generic versions of levofloxacin had been available since 2004 and marketed as a generic drug under a variety of different brand names. However, Daiichi Sankyo-Johnson and Johnson-Ortho McNeil filed numerous patent lawsuits to prevent such generic equivalents from being marketed, claiming that their patent did not expire until 23 June 2009. see Generic equivalents
Regulatory history in the United States
Levofloxacin was first patented in 1987, and was subsequently approved for use in Japan (1 October 1993), Korea (4 April 1994), Hong Kong (3 October 1994), and China (3 May 1995). Levofloxacin received FDA approval in the United States 20 December 1996. Floxin (ofloxacin – floxacin) was patented in 1982 (European patent Daiichi) and received FDA approval 28 December 1990. The U.S. patent is owned by Daiichi Sankyo and exclusively licensed to Ortho-McNeil.
Many of the clinical isolates that were initially tested within the NDA for levofloxacin against Floxin (ofloxacin –floxacin) disks instead of levofloxacin disks but reported as susceptible or resistant to levofloxacin. When levofloxacin disks were not available in early clinical trials, a 5-pg Floxin (ofloxacin –floxacin) disk was substituted. The FDA medical reviewers considered the two drugs to be one and the same and hence interchangeable.
- 12 March 2009
The FDA requested updating the carton and container labels to include a statement to let dispensers know that a Medication Guide must be dispensed with the product, in compliance with the Medication Guide Regulations as specified in 21 CFR 208.24 (d).
- 27 April 2009
Issuance of a Medication Guide and revisions to include new safety information. The FDA has determined that levofloxacin poses a serious and significant public health concern, requiring the distribution of a Medication Guide. However the Medication Guide does not include any boxed warnings.
- 25 February 2011
Additional boxed warning added to all the drugs within this class, including levofloxacin, stating that the fluoroquinolone class may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Such an adverse reaction is a potentially life-threatening event and may require ventilatory support.
Note: Although the FDA had requested that the revised labeling (which were to include the boxed warnings) accompany the package inserts for any newly shipped products (effective January 2009) there are continuing reports that as of July 2009, that the products continue to contain the older labels, and not the revised labels, and that the Medication Guides (absent of the boxed warnings) were not made available for distribution.
Antibiotic abuse and bacterial resistance
Resistance to levofloxacin and other fluoroquinolones may evolve rapidly, even during a course of treatment. Numerous pathogens, including Staphylococcus aureus, enterococci, and Streptococcus pyogenes now exhibit resistance worldwide. There are three known mechanisms of resistance. Some types of efflux pumps can act to decrease intracellular quinolone concentration. In gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or Topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drug's effectiveness.
Years ago, the FDA had added warnings regarding the proper use of Levaquin within the package inserts to combat such prescription abuse. Advising physicians that levofloxacin: "...should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria...."
Though considered to be a very important and necessary drug required to treat severe and life-threatening bacterial infections, the associated prescription abuse of levofloxacin remains unchecked, which has contributed to the problem of bacterial resistance. The overuse of antibiotics, such as happens with children suffering from otitis media, has given rise to a breed of super-bacteria that are resistant to antibiotics entirely.
Fluoroquinolones, including levofloxacin, had become the most commonly prescribed class of antibiotics to adults in 2002. Nearly half (42%) of these prescriptions were for conditions not approved by the FDA, such as acute bronchitis, otitis media, and acute upper respiratory tract infection, according to a study that was supported in part by the Agency for Healthcare Research and Quality. In addition, they are commonly prescribed for medical conditions that are not even bacterial to begin with, such as viral infections, or those to which no proven benefit exists.
Social and economic impact
From 2001–2008, patent extension legislation was signed into law that allowed a six-month patent extension for testing their products for safety in children, an under-represented category in clinical trials. The FDA granted Johnson and Johnson–Ortho McNeil pediatric exclusivity for Levaquin. This extended their patent until the end of 2010.
In 2005, the US Court of Appeals for the Federal Circuit had affirmed the validity of US patent (No. 5,053,407) on levofloxacin, held by Daiichi Sankyo Co., Ltd. On 17 October 2006, Daiichi Sankyo also won a patent infringement lawsuit in Canada involving the generic version of Levaquin. The Canadian Federal Appeals Court upheld a lower court's ruling handed down last October, which accepted the validity of Daiichi Sankyo's patent until 23 June 2009. Daiichi Sankyo and Janssen-Ortho Inc., a Johnson & Johnson subsidiary, filed a lawsuit with a federal court in Toronto after Teva Novopharm Ltd., started selling the generic version of levofloxacin in December 2004. The Canadian Federal Court in Toronto ordered Novopharm to suspend selling the generic version of the drug. Unsatisfied with the ruling, Novopharm appealed to the higher court. On 7 June 2007, the Canadian Federal Appeal Court dismissed this appeal. Novopharm was prevented from making, using, offering to sell, or selling a generic version of levofloxacin tablets in the Canadian market until the expiration of patent on 23 June 2009. Novopharm's generic version of Levaquin, had been sold in Canada since 2004.
There are also cases currently pending before the United States District Court, District of Minnesota, involving Levaquin. On 13 June 2008, a Judicial Panel On Multidistrict Litigation (MDL) granted the Plaintiffs' motion to centralize individual and class action lawsuits involving Levaquin in the District of Minnesota over objection of Defendants, Johnson and Johnson / Ortho McNeil.
On 6 July 2009, The New Jersey Supreme Court had also designated litigation over Levaquin as a mass tort and has assigned it to an Atlantic County, N.J., judge. The suits charge that the drug has caused achilles tendon ruptures and other permanent damage. Additional lawsuits have also been recently filed in the Illinois State Court. Of a total of about 3400 cases, 845 were recently settled out of court after Johnson and Johnson prevailed in three of the first four cases to go to trial
An official complaint has been filed by The US Justice Department with a Federal Court in Boston (January 2010) accusing Johnson and Johnson of illegally paying millions of dollars in kickbacks to Omnicare, one of the nation's largest pharmacies specializing in nursing home patients. In return, Omnicare nearly tripled its annual purchase of Johnson and Johnson's products; including Levaquin.
On 8 April 2010 in the Beaumont Division of the Eastern District of Texas, a class action lawsuit was filed by Lisa Presley on behalf of herself and others similar situated against Johnson and Johnson, Ortho-McNeil Pharmaceuticals Inc. and Johnson and Johnson Pharmaceutical Research and Development LLC. (Case No 1:10cv00200.)
The various manufacturers have countered these allegations stating that they believe that these drugs are both safe and effective antibiotics, well tolerated with a minimum of side-effects, that such reactions are rare and the benefits of such therapy outweigh the perceived risks.
- Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. (Apr 2007). "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story.". Clin Infect Dis 44 (7): 977–80. doi:10.1086/512369. PMID 17342653.
- Kawahara, S. (Dec 1998). "[Chemotherapeutic agents under study]". Nippon Rinsho 56 (12): 3096–9. PMID 9883617.
- Laurence Brunton; John Lazo; Keith Parker (23 August 2005). Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill Prof Med/Tech. ISBN 978-0-07-142280-2. Retrieved 30 October 2012.
- Mandell LA, Wunderink RG, Anzueto A, et al. (March 2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clin. Infect. Dis. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083.
- "National Guideline Clearinghouse | Treatment of urinary tract infections in nonpregnant women.".
- Solomkin JS, Mazuski JE, Bradley JS, et al. (January 2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clin. Infect. Dis. 50 (2): 133–64. doi:10.1086/649554. PMID 20034345.
- Morrissey I, Hoshino K, Sato K, Yoshida A, Hayakawa I, Bures MG, Shen LL.,Mechanism of differential activities of ofloxacin enantiomers, in Antimicrob Agents Chemother. 1996 Aug;40(8):1775-84
- Janssen Pharmaceutica (September 2008). "Highlights of Prescribing Information". U.S. Food and Drug Administration (FDA).
- Morrissey, I.; Hoshino, K.; Sato, K.; Yoshida, A.; Hayakawa, I.; Bures, MG.; Shen, LL. (August 1996). "Mechanism of differential activities of ofloxacin enantiomers" (PDF). Antimicrob Agents Chemother 40 (8): 1775–84. PMC 163416. PMID 8843280.
- "Levofloxacin". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- Mark J. Goldberger (17 December 1998). "Center for drug evaluation and research". U.S. Food and Drug Administration (FDA).
- Mark J. Goldberger. "NDA 20-634/S-008, S-009, NDA 20-635/S-007, S-008". U.S. Food and Drug Administration (FDA).
- Renata Albrecht,. "NDA 20-634/S-013, NDA 20-635/S-010". U.S. Food and Drug Administration (FDA).
- Renata Albrecht. "NDA 20-634/S-025, NDA 20-635/S-022". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (23 May 2003). "NDA 20-634/S-027, NDA 20-635/S-026". U.S. Food and Drug Administration (FDA).
- Schaeffer AJ (September 2004). "NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis". Int. J. Antimicrob. Agents. 24 Suppl 1: S49–52. doi:10.1016/j.ijantimicag.2004.02.009. PMID 15364307.
- Renata Albrecht (24 November 2004). "NDA 20-634/S-035, NDA 20-635/S-035, NDA 21-721/S-003". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (8 April 2005). "NDA 20-634/S-037, NDA 20-635/S-038, NDA 21-721/S-002". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (23 June 2006). "NDA 20-634/S-040, NDA 20-635/S-043, NDA 21-721/S-007". U.S. Food and Drug Administration (FDA).
- "FDA OKs Levaquin To Treat Plague". RTTNews. 29 April 2012.
- Renata Albrecht (5 May 2008). "NDA 20-634/S-047, NDA 20-635/S-051, NDA 21-721/S-015". U.S. Food and Drug Administration (FDA).
- John A. Bosso (1998). "New and Emerging Quinolone Antibiotics". Journal of Infectious Disease Pharmacotherapy 2 (4): 61–76. doi:10.1300/J100v02n04_06. ISSN 1068-7777.
- "SYNOPSIS" (PDF). veritasmedicine.com. 6 September 2005.
- Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy in a child". Journal of Postgraduate Medicine 53 (2): 144–5. doi:10.4103/0022-3859.32220. PMID 17495385.
- Division of Special Pathogen and Immunologic Drug Products Summary of Clinical Review of Studies Submitted in Response to a Pediatric Written Request
- Chalumeau M, Tonnelier S, D'Athis P (June 2003). "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France". Pediatrics 111 (6 Pt 1): e714–9. doi:10.1542/peds.111.6.e714. PMID 12777590. Retrieved 29 June 2009.
- Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I (October 2005). "Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection". Ann Pharmacother 39 (10): 1737–40. doi:10.1345/aph.1G111. PMID 16105873.
- Shin HC, Kim JC, Chung MK (September 2003). "Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats". Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (1): 95–102. doi:10.1016/j.cca.2003.08.004. PMID 14522602.
- Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrob. Agents Chemother. 37 (2): 293–6. doi:10.1128/AAC.37.2.293. PMC 187655. PMID 8452360.
- Noel GJ, Bradley JS, Kauffman RE (October 2007). "Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders". Pediatr. Infect. Dis. J. 26 (10): 879–91. doi:10.1097/INF.0b013e3180cbd382. PMID 17901792.
- Owens Rc, Jr; Ambrose, PG (July 2005). "Antimicrobial safety: focus on fluoroquinolones". Clinical Infectious Diseases. 41 Suppl 2: S144–57. doi:10.1086/428055. ISSN 1058-4838. PMID 15942881.
- U S Food and Drug Administration (8 July 2008). "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs". U.S. Food and Drug Administration (FDA). Retrieved 5 September 2009.
- US Food and Drug Administration (2008). "Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin and generic ofloxacin)]". USA. Retrieved 5 September 2009.[dead link]
- US Food and Drug Administration. "Drugs at FDA: FDA Approved Drug Products". USA: U.S. Food and Drug Administration (FDA). Retrieved 5 September 2009.
- Renata Albrecht (14 September 2004). "NDA 20-634/S-033, S-034, NDA 20-635/S-033, S-034". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (14 July 2004). "NDA 19-537/S-053, S-054, NDA 20-780/S-017, S-018". U.S. Food and Drug Administration (FDA). Retrieved 5 September 2009.
- Renata Albrecht (18 December 2001). "NDA 20-634/S-015, S-021, S-022, NDA 20-635/S-012, S-019, S-020". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (4 November 2004). "NDA 20-634/S-036, NDA 20-635/S-037". U.S. Food and Drug Administration (FDA).
- Petitjeans, F.; Nadaud, J.; Perez, JP.; Debien, B.; Olive, F.; Villevieille, T.; Pats, B. (December 2003). "A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin". Eur J Clin Pharmacol 59 (10): 779–80. doi:10.1007/s00228-003-0688-x. PMID 14576967.
- Hsiao, SH.; Chang, CM.; Tsao, CJ.; Lee, YY.; Hsu, MY.; Wu, TJ. (January 2005). "Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy". Ann Pharmacother 39 (1): 146–9. doi:10.1345/aph.1E285. PMID 15562138.
- Korzets, A.; Gafter, U.; Dicker, D.; Herman, M.; Ori, Y. (November 2006). "Levofloxacin and rhabdomyolysis in a renal transplant patient". Nephrol Dial Transplant 21 (11): 3304–5. doi:10.1093/ndt/gfl396. PMID 16968728.
- Renata Albrecht (31 May 2007). "NDA 20-634/S-042, NDA 20-635/S-045, NDA 21-721/S-010". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (19 June 2006). "NDA 19-537/S-062, NDA 20-780/S-023, NDA 19-847/S-037, NDA 19-857/S-042, NDA 21-473/S-016". U.S. Food and Drug Administration (FDA). Retrieved 5 September 2009.
- Renata Albrecht (5 March 2004). "NDA 20-634/S-029, NDA 20-635/S-029". U.S. Food and Drug Administration (FDA).
- Cohen JS (December 2001). "Peripheral Neuropathy Associated with Fluoroquinolones" (PDF). Ann Pharmacother 35 (12): 1540–7. doi:10.1345/aph.1Z429. PMID 11793615.
- Renata Albrecht (19 June 2007). "NDA 20-634/S-045, NDA 20-635/S-048, NDA 21-721/S-013" (PDF). USA: U.S. Food and Drug Administration (FDA).
- Renata Albrecht (16 April 2008). "NDA 20-634/S-051, NDA 20-635/S-055, NDA 21-721/S-019". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (15 March 2004). "NDA 19-537/S-048, S-050, S-051 NDA 20-780/S-012, S-014, S-015". U.S. Food and Drug Administration (FDA). Retrieved September 2009.
- Renata Albrecht (3 October 2008). "NDA 20-634/S-052, NDA 20-635/S-057, NDA 21-721/S-020". U.S. Food and Drug Administration (FDA).
- Renata Albrecht (3 October 2008). "NDA 19-537/S-068, NDA 19-847/S-042, NDA 19-857/S-049, NDA 20-780/S-026, NDA 21-473/S-024". U.S. Food and Drug Administration (FDA). Retrieved 5 September 2009.
- Renata Albrecht (13 December 2007). "NDA 20-634/S-050, NDA 20-635/S-054, NDA 21-721/S-018". U.S. Food and Drug Administration (FDA).
- Kushner, JM.; Peckman, HJ.; Snyder, CR. (October 2001). "Seizures associated with fluoroquinolones". Ann Pharmacother 35 (10): 1194–8. doi:10.1345/aph.10359. PMID 11675843.
- Ozawa, TT.; Valadez, T. (March 2002). "Clostridium difficile infection associated with levofloxacin treatment". Tenn Med 95 (3): 113–5. PMID 11898264.
- Gopal Rao, G.; Mahankali Rao, CS.; Starke, I. (March 2003). "Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy". J Antimicrob Chemother 51 (3): 697–701. doi:10.1093/jac/dkg115. PMID 12615873.
- Muto CA, Pokrywka M, Shutt K (March 2005). "A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use". Infect Control Hosp Epidemiol 26 (3): 273–80. doi:10.1086/502539. PMID 15796280.
- Deshpande, A.; Pant, C.; Jain, A.; Fraser, TG.; Rolston, DD. (February 2008). "Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence". Curr Med Res Opin 24 (2): 329–33. doi:10.1185/030079908X253735. PMID 18067688.
- Cho, S.; Breedlove, JJ.; Gunning, ST. (January 2008). "Radiation recall reaction induced by levofloxacin". J Drugs Dermatol 7 (1): 64–7. PMID 18246700.
- Smythe, MA.; Cappelletty, DM. (December 2000). "Anaphylactoid reaction to levofloxacin". Pharmacotherapy 20 (12): 1520–3. doi:10.1592/phco.20.19.1520.34868. PMID 11130225.
- Takahama, H.; Tsutsumi, Y.; Kubota, Y. (September 2005). "Anaphylaxis due to levofloxacin". Int J Dermatol 44 (9): 789–90. doi:10.1111/j.1365-4632.2004.02325.x. PMID 16135155.
- Gunduz, A.; Turedi, S.; Kalkan, A.; Nuhoglu, I. (August 2006). "Levofloxacin induced myasthenia crisis". Emerg Med J 23 (8): 662. doi:10.1136/emj.2006.038091. PMC 2564188. PMID 16858118.
- Mennecier, D.; Thiolet, C.; Bredin, C.; Potier, V.; Vergeau, B.; Farret, O. (October 2001). "[Acute pancreatitis after treatment by levofloxacin and methylprednisolone]". Gastroenterol Clin Biol 25 (10): 921–2. PMID 11852403.
- Domínguez Jiménez, JL.; Bernal Blanco, E.; Marín Moreno, MA.; Puente Gutiérrez, JJ. (April 2009). "[Acute pancreatitis associated with levofloxacin]". Gastroenterol Hepatol (in Spanish) 32 (4): 323–4. doi:10.1016/j.gastrohep.2008.09.027. PMID 19371975.
- Fraunfelder, FW.; Fraunfelder, FT. (September 2009). "Diplopia and fluoroquinolones". Ophthalmology 116 (9): 1814–7. doi:10.1016/j.ophtha.2009.06.027. PMID 19643481.
- Grépinet, C.; Guillocheau, E.; Berteloot, A.; Vachée, A.; Herbin, O.; Gautier, S.; l'association des centres régionaux de pharmacovigilance (2008). "[Drug-induced fever during treatment with levofloxacin: a case-report]". Therapie 63 (4): 341–3. PMID 19043827.
- Lardizabal, DV. (February 2009). "Intracranial hypertension and levofloxacin: a case report". Headache 49 (2): 300–1. doi:10.1111/j.1526-4610.2008.01212.x. PMID 18647180.
- Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG (2003). "Levofloxacin-induced autoimmune hemolytic anemia". Ann Pharmacother 37 (7–8): 1010–3. doi:10.1345/aph.1C525. PMID 12841809.
- Iannini, PB. (June 2007). "The safety profile of moxifloxacin and other fluoroquinolones in special patient populations". Curr Med Res Opin 23 (6): 1403–13. doi:10.1185/030079907X188099. PMID 17559736.
- Owens, RC.; Ambrose, PG. (July 2005). "Antimicrobial safety: focus on fluoroquinolones". Clin Infect Dis. 41 Suppl 2: S144–57. doi:10.1086/428055. PMID 15942881.
- Saint, F.; Gueguen, G.; Biserte, J.; Fontaine, C.; Mazeman, E. (September 2000). "[Rupture of the patellar ligament one month after treatment with fluoroquinolone]". Rev Chir Orthop Reparatrice Appar Mot 86 (5): 495–7. PMID 10970974.
- Gangopadhyay, N.; Daniell, M.; Weih, L.; Taylor, HR. (April 2000). "Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers". Br J Ophthalmol 84 (4): 378–84. doi:10.1136/bjo.84.4.378. PMC 1723447. PMID 10729294.
- Walter, K.; Tyler, ME. (August 2006). "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases". Cornea 25 (7): 855–7. doi:10.1097/01.ico.0000224642.43601.14. PMID 17068466.
- "Public Citizen Warns of Cipro Dangers". USA: Consumer affairs. 30 August 2006. Retrieved 7 September 2009.
- "FDA orders 'black box' label on some antibiotics". CNN. 8 July 2008. Retrieved 8 July 2008.
- Hirano T, Yasuda S, Osaka Y (March 2008). "The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo". International Journal of Pharmaceutics 351 (1–2): 113–8. doi:10.1016/j.ijpharm.2007.09.022. PMID 17977676.
- Friedrich, LV.; Dougherty, R. (December 2004). "Fatal hypoglycemia associated with levofloxacin". Pharmacotherapy 24 (12): 1807–12. doi:10.1592/phco.24.17.1807.52348. PMID 15585448.
- Melissa Hunt (January 2007). "Levofloxacin: dysglycemia and liver disorders" (PDF). Canadian adverse reaction newsletter (Canada: Health Canada Newsletter) 17 (1). [dead link]
- Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteersTaubel, Jorg; Naseem, A., Harada, T., Wang, D., Arezina, R., Lorch, U. and Camm, A. J. (2010) (November 2009). "Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers". British Journal of Clinical Pharmacology 69 (4): 391–400. doi:10.1111/j.1365-2125.2009.03595.x. PMC 2848412. PMID 20406223.
- DrugBank (19 February 2009). "Showing drug card for Levofloxacin (DB01137)". Canada.
- "Showing drug card for Rimantadine (DB00478)". Canada. 23 June 2009.
- Drlica K, Zhao X (1 September 1997). "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 377–92. PMC 232616. PMID 9293187.
- Brouwers JR (1992). "Drug interactions with quinolone antibacterials". Drug Saf 7 (4): 268–81. doi:10.2165/00002018-199207040-00003. PMID 1524699.
- Hilliard JJ, Krause HM, Bernstein JI (1995). "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase". Adv Exp Med Biol. 390: 59–69. PMID 8718602.
- Cooper JG, Harboe K, Frost SK, Skadberg Ø (April 2005). "Ciprofloxacin interacts with thyroid replacement therapy". BMJ 330 (7498): 1002. doi:10.1136/bmj.330.7498.1002. PMC 557149. PMID 15860826.
- Domagala JM (April 1994). "Structure-activity and structure-side-effect relationships for the quinolone antibacterials". J. Antimicrob. Chemother. 33 (4): 685–706. doi:10.1093/jac/33.4.685. PMID 8056688.
- Janknegt R (November 1990). "Drug interactions with quinolones". J. Antimicrob. Chemother. 26 Suppl D: 7–29. doi:10.1093/jac/26.suppl_D.7. PMID 2286594.
- van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003). "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids". Arch. Intern. Med. 163 (15): 1801–7. doi:10.1001/archinte.163.15.1801. PMID 12912715.
- Zacher, JL; Givone, DM (2004). "False-positive urine opiate screening associated with fluoroquinolone use". Ann Pharmacother (38): 1525–1528.
- University of Maryland Medical Center. "Levofloxacin". USA: University of Maryland.
- Takashi Shoda (23 October 2008). "UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court". USA: Daiichi Sankyo, Limited.[dead link]
- Johnson & Johnson (2009). "Analysis of Sales by Business Segments" (PDF). Shareholder. p. 27.
- "LEVAQUIN". USA: drugpatentwatch.com.
- "Levofloxacin". Tuberculosis (Edinb) 88 (2): 119–21. March 2008. doi:10.1016/S1472-9792(08)70013-1. PMID 18486047.
- North DS, Fish DN, Redington JJ (1998). "Levofloxacin, a second-generation fluoroquinolone". Pharmacotherapy 18 (5): 915–35. PMID 9758306.
- edited by Thomas L. Lemke, David A. Williams ; assistant editors, Victoria F. Roche, S. William Zito ..., Thomas L.; Williams, David A. (1 October 2007). Foye's Principles of Medicinal Chemistry (6 ed.). USA: Lippincott Williams & Wilkins. ISBN 978-0-7817-6879-5. More than one of
- "Levaquin Information". USA: Medications.com.
- King DE, Malone R, Lilley SH (May 2000). "New classification and update on the quinolone antibiotics". American Family Physician 61 (9): 2741–8. PMID 10821154. Retrieved 30 June 2009.
- Davis R, Bryson HM (April 1994). "Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy". Drugs 47 (4): 677–700. doi:10.2165/00003495-199447040-00008. PMID 7516863.
- "STATISTICAL REVIEW AND EVALUATION" (PDF). USA: U.S. Food and Drug Administration (FDA). 21 November 1996.
- Ed Lamb (1 May 2008). "Top 200 Prescription Drugs of 2007". Pharmacy Times. Retrieved 21 July 2009.[dead link]
- Cravit, Cravit Ophthalmic, Elequine, Floxel, Iquix, Leroxacin, Lesacin, Levaquin, Levokacin, Levox, Levoxacin, Mosardal, Nofaxin, Quixin, Reskuin, Tavanic, Volequin http://www.drugbank.ca/drugs/DB01137
- Cravox, Floxlevo, Levoxacine, Levoxetina, Nislev, Oftaquix, Prixar, Reskuin, Tavanic source: http://www.umm.edu/altmed/drugs/levofloxacin-075755.htm#International%20Brand%20Names
- "Novopharm Limited". USA. 3 November 2009.
- JOHNSON & JOHNSON (28 March 2004). "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". USA: shareholder.com. pp. 28–29.
- "NDA 20-634/S-054, NDA 20-635/S-059, NDA 21-721/S-022". U.S. Food and Drug Administration (FDA). 12 March 2009.
- Ozlem Belen (27 March 2009). "NDA 20-634/S-053, NDA 20-635/S-058, NDA 21-721/S-021". U.S. Food and Drug Administration (FDA).
- Ortho-McNeil-Janssen Pharmaceuticals, Inc. (October 2008). "FDA-Approved Medication Guide". U.S. Food and Drug Administration (FDA).
- Levaquin (Levofloxacin)
- Renata Albrecht (3 October 2008). "NDA 19-735/S-059". U.S. Food and Drug Administration (FDA).
- M Jacobs, Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.
- Robicsek A, Jacoby GA, Hooper DC (October 2006). "The worldwide emergence of plasmid-mediated quinolone resistance". The Lancet Infectious Diseases 6 (10): 629–40. doi:10.1016/S1473-3099(06)70599-0. PMID 17008172.
- Froom J, Culpepper L, Jacobs M (July 1997). "Antimicrobials for acute otitis media? A review from the International Primary Care Network". BMJ (Clinical Research Ed.) 315 (7100): 98–102. doi:10.1136/bmj.315.7100.98. PMC 2127061. PMID 9240050.
- Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS (March 2005). "Fluoroquinolone prescribing in the United States: 1995 to 2002". The American Journal of Medicine 118 (3): 259–68. doi:10.1016/j.amjmed.2004.09.015. PMID 15745724.
- K08 HS14563 and HS11313
- "Levaquin MDL | 08-MD-1943". USA: US District Court District of Minnesota. Retrieved 7 September 2009.
- Charles Toutant (6 July 2009). "Litigation Over Johnson & Johnson Antibiotic Levaquin Designated N.J. Mass Tort". New Jersey Law Journal.
- Reed Abelson; Natasha Singer (14 October 2011). "Johnson & Johnson Wins Suit Over Antibiotic's Side Effects". The New York Times.
- "Levaquin MDL | United States District Court – District of Minnesota, United States District Court – District of Minnesota".
- "Johnson & Johnson Settles 845 Levaquin Lawsuits – Businessweek".
- The Southeast Texas Record. 17 April 2010 S.E. Texas' Legal Journal Class action alleges antibiotic causes tendon damage 15 April 2010 8:21 am By Michelle Massey, East Texas Bureau http://www.setexasrecord.com/news/226050-class-action-alleges-antibiotic-causes-tendon-damage
- Levofloxacin at the Open Directory Project
- U.S. National Library of Medicine: Drug Information Portal – Levofloxacin
- Levaquin Package Insert
- Iquix Package Insert
- Quixin Package Insert